United States - English - NLM (National Library of Medicine)

dr. reddy's laboratories inc - amoxicillin (unii: 804826j2hu) (amoxicillin anhydrous - unii:9em05410q9), clavulanate potassium (unii: q42omw3at8) (clavulanic acid - unii:23521w1s24) - amoxicillin anhydrous 250 mg - to reduce the development of drug‑resistant bacteria and maintain the effectiveness of augmentin (amoxicillin/clavulanate potassium) and other antibacterial drugs, augmentin should be used only to treat infections that are proven or strongly suspected to be caused by susceptible bacteria. when culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. in the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. augmentin® is a combination penicillin-class antibacterial and beta-lactamase inhibitor indicated in the treatment of infections due to susceptible isolates of the designated bacteria in the conditions listed below*: caused by beta‑lactamase–producing isolates of haemophilus influenzae and moraxella catarrhalis . caused by beta‑lactamase–producing isolates of h. influenzae and m. catarrhalis . caused by beta‑lactamase–producing isolates of h. influenzae and m. catarr

United States - English - NLM (National Library of Medicine)

neopharma inc - amoxicillin (unii: 804826j2hu) (amoxicillin anhydrous - unii:9em05410q9), clavulanate potassium (unii: q42omw3at8) (clavulanic acid - unii:23521w1s24) - to reduce the development of drug‑resistant bacteria and maintain the effectiveness of augmentin (amoxicillin/clavulanate potassium) and other antibacterial drugs, augmentin should be used only to treat infections that are proven or strongly suspected to be caused by susceptible bacteria. when culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. in the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. augmentin®  is a combination penicillin-class antibacterial and beta-lactamase inhibitor indicated in the treatment of infections due to susceptible isolates of the designated bacteria in the conditions listed below*:  caused by beta‑lactamase–producing isolates of haemophilus influenzae and moraxella catarrhalis .  caused by beta‑lactamase–producing isolates of h. influenzae and m. catarrhalis .  caused by beta‑lactamase–producing isolates of h. influenzae and m. cat

New Zealand - English - Medsafe (Medicines Safety Authority)

glaxosmithkline nz limited - amoxicillin sodium 1060.2mg equivalent to amoxicillin 1000 mg;  ; potassium clavulanate 238.25mg equivalent to clavulanic acid 200 mg;  ;  ;   - powder for injection - 1.2 g - active: amoxicillin sodium 1060.2mg equivalent to amoxicillin 1000 mg   potassium clavulanate 238.25mg equivalent to clavulanic acid 200 mg       - augmentin is indicated for the short term treatment of common bacterial infections such as: -upper respiratory tract infections (including ent): e.g. tonsillitis, sinusitis, otitis media -lower respiratory tract infections: e.g. acute exacerbations of chronic bronchitis, lobar and broncho-pneumonia -genito-urinary tract infections: e.g. cystitis, urethritis, pyelonephritis, female genital infections -skin and soft tissue infections -bone and joint infections: e.g. osteomyelitis -other infections: e.g. septic abortion, puerperal sepsis, intra-abdominal sepsis, septicaemia, peritonitis, post-surgical infections augmentin is indicated for prophylaxis against infection which may be associated with major surgical procedures such as gastro-intestinal, pelvic, head and neck, cardiac, renal, joint replacement and biliary tract surgery.

New Zealand - English - Medsafe (Medicines Safety Authority)

glaxosmithkline nz limited - amoxicillin sodium 530.1mg equivalent to amoxicillin 500 mg;  ; potassium clavulanate 119.13mg equivalent to clavulanic acid 100 mg;  ;  ;   - powder for injection - 600 mg - active: amoxicillin sodium 530.1mg equivalent to amoxicillin 500 mg   potassium clavulanate 119.13mg equivalent to clavulanic acid 100 mg       - augmentin is indicated for the short term treatment of common bacterial infections such as: -upper respiratory tract infections (including ent): e.g. tonsillitis, sinusitis, otitis media -lower respiratory tract infections: e.g. acute exacerbations of chronic bronchitis, lobar and broncho-pneumonia -genito-urinary tract infections: e.g. cystitis, urethritis, pyelonephritis, female genital infections -skin and soft tissue infections -bone and joint infections: e.g. osteomyelitis -other infections: e.g. septic abortion, puerperal sepsis, intra-abdominal sepsis, septicaemia, peritonitis, post-surgical infections augmentin is indicated for prophylaxis against infection which may be associated with major surgical procedures such as gastro-intestinal, pelvic, head and neck, cardiac, renal, joint replacement and biliary tract surgery.

Singapore - English - HSA (Health Sciences Authority)

glaxosmithkline pte ltd - amoxycillin trihydrate 459.17mg/5ml eqv amoxycillin; potassium clavulanate 67.9mg/5ml eqv clavulanic acid - powder, for suspension - 400 mg/5 ml - amoxycillin trihydrate 459.17mg/5ml eqv amoxycillin 400 mg/5 ml; potassium clavulanate 67.9mg/5ml eqv clavulanic acid 57 mg/5 ml

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

lexon (uk) ltd - amoxicillin trihydrate; potassium clavulanate - oral tablet - 500mg ; 125mg

Israel - English - Ministry of Health

glaxo smith kline (israel) ltd - amoxicillin as trihydrate; clavulanic acid as potassium salt - film coated tablets - amoxicillin as trihydrate 875 mg; clavulanic acid as potassium salt 125 mg - ampicillin and enzyme inhibitor - ampicillin and enzyme inhibitor - augmentin is indicated for the treatment of the following infections in adults and children :• acute bacterial sinusitis (adequately diagnosed)• acute otitis media• acute exacerbations of chronic bronchitis (adequately diagnosed)• community acquired pneumonia• cystitis• pyelonephritis• skin and soft tissue infections in particular cellulitis, animal bites, severe dental abscess with spreading cellulitis.• bone and joint infections, in particular osteomyelitis.

Armenia - English - Դեղերի և բժշկական տեխնոլոգիաների փորձագիտական կենտրոնի գործունեության Հայաստանի Հանրապետությունում

smithkline beecham limited - amoxicillin (amoxicillin trihydrate), clavulanic acid (potassium clavulanate) - tablets film-coated - 250mg+ 125mg

Armenia - English - Դեղերի և բժշկական տեխնոլոգիաների փորձագիտական կենտրոնի գործունեության Հայաստանի Հանրապետությունում

smithkline beecham limited - amoxicillin (amoxicillin trihydrate), clavulanic acid (potassium clavulanate) - powder for oral suspension - 125mg/5ml+ 31,25mg/5ml

Armenia - English - Դեղերի և բժշկական տեխնոլոգիաների փորձագիտական կենտրոնի գործունեության Հայաստանի Հանրապետությունում

smithkline beecham limited - amoxicillin (amoxicillin trihydrate), clavulanic acid (potassium clavulanate) - powder for oral suspension - 250mg/5ml+ 62,5mg/5ml